Cipla: Company Gets USFDA Approval for Generic Advair Diskus in All Three Strengths for Asthma and COPD Treatment.

 28 Jul 2026 07:57 AM

Cipla: Company Gets USFDA Approval for Generic Advair Diskus in All Three Strengths for Asthma and COPD Treatment.

Cipla: JPM on Cipla Maintains Overweight with Target Price of ₹1,600 as Q1 EBITDA margin missed estimates but FY27 margin guidance was retained, supported by a strong US launch pipeline and operating leverage.

 24 Jul 2026 09:02 AM

Cipla: JPM on Cipla Maintains Overweight with Target Price of ₹1,600 as Q1 EBITDA margin missed estimates but FY27 margin guidance was retained, supported by a strong US launch pipeline and operating leverage.

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Q1 was largely in line, FY27 margin guidance was retained, and robust India growth plus improving US launches support FY28 earnings upside.

 24 Jul 2026 09:02 AM

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Q1 was largely in line, FY27 margin guidance was retained, and robust India growth plus improving US launches support FY28 earnings upside.

Cipla: Nomura on Cipla Maintains Buy with Target Price of ₹1,510 as Q1 EBITDA margin missed estimates, but retained FY27 margin guidance and high-value US launches are expected to drive margin recovery.

 24 Jul 2026 09:02 AM

Cipla: Nomura on Cipla Maintains Buy with Target Price of ₹1,510 as Q1 EBITDA margin missed estimates, but retained FY27 margin guidance and high-value US launches are expected to drive margin recovery.

Cipla: Upcoming US Pipeline Has Four Major Launches, Featuring Three Respiratory Products (One Being Generic Advair) And One Important Peptide Product. Two Respiratory Products Filed From US Facilities, And One From Goa Facility.

 24 Jul 2026 08:34 AM

Cipla: Upcoming US Pipeline Has Four Major Launches, Featuring Three Respiratory Products (One Being Generic Advair) And One Important Peptide Product. Two Respiratory Products Filed From US Facilities, And One From Goa Facility.

Cipla: North America Business Anticipates Ongoing Growth This Year Due To Upcoming Product Launches And Ongoing Sales Efforts, With A Target Of Reaching A $1 Billion Run Rate By FY27, Depending On New Product Approvals And Increased Ventolin Production.

 24 Jul 2026 08:34 AM

Cipla: North America Business Anticipates Ongoing Growth This Year Due To Upcoming Product Launches And Ongoing Sales Efforts, With A Target Of Reaching A $1 Billion Run Rate By FY27, Depending On New Product Approvals And Increased Ventolin Production.

Cipla: Company Achieves Record Q1 Revenue of INR 7,100 Crore for FY27, Demonstrating Strong Business Resilience. || FY27 EBITDA Margin Guidance Stays the Same at 18.5% to 20% Based on New Product Launches and Expected Margin Growth.

 24 Jul 2026 08:35 AM

Cipla: Company Achieves Record Q1 Revenue of INR 7,100 Crore for FY27, Demonstrating Strong Business Resilience. || FY27 EBITDA Margin Guidance Stays the Same at 18.5% to 20% Based on New Product Launches and Expected Margin Growth.

Cipla: Global CEO Gupta - Tariffs Is An Evolving Situation, We Will Monitor It || Tariffs Is An Evolving Situation, We Will Monitor It

 23 Jul 2026 03:18 PM

Cipla: Global CEO Gupta - Tariffs Is An Evolving Situation, We Will Monitor It || Tariffs Is An Evolving Situation, We Will Monitor It

Cipla: Expects Upcoming Reinspection Of Indore Facility; Four New Products In Development. - Concall Update

 23 Jul 2026 03:18 PM

Cipla: Expects Upcoming Reinspection Of Indore Facility; Four New Products In Development. - Concall Update

Cipla: Global CEO - Have Experience In Diversifying Manufacturing, We Will Be Able To Adapt

 23 Jul 2026 03:19 PM

Cipla: Global CEO - Have Experience In Diversifying Manufacturing, We Will Be Able To Adapt

Cipla: Plans Exciting Product Launches And Looks To Improve Distribution Network. - Concall Update

 23 Jul 2026 03:19 PM

Cipla: Plans Exciting Product Launches And Looks To Improve Distribution Network. - Concall Update

Cipla: Co. Retains 18-20% EBITDA Margin Forecast For FY27 - Concall Update

 23 Jul 2026 03:21 PM

Cipla: Co. Retains 18-20% EBITDA Margin Forecast For FY27 - Concall Update

CIPLA: Q1 CONS NET PROFIT 8B RUPEES VS 13B (YOY); EST 9.23B

 23 Jul 2026 11:57 AM

CIPLA: Q1 CONS NET PROFIT 8B RUPEES VS 13B (YOY); EST 9.23B

CIPLA: Q1 REVENUE 71.19B RUPEES VS 69.6B (YOY); EST 73.4B

 23 Jul 2026 11:58 AM

CIPLA: Q1 REVENUE 71.19B RUPEES VS 69.6B (YOY); EST 73.4B

CIPLA: Q1 EBITDA 11.9B RUPEES VS 17.78B (YOY); EST 13.76B || Q1 EBITDA MARGIN 16.75% VS 25.56% (YOY); EST 18.7%

 23 Jul 2026 11:58 AM

CIPLA: Q1 EBITDA 11.9B RUPEES VS 17.78B (YOY); EST 13.76B || Q1 EBITDA MARGIN 16.75% VS 25.56% (YOY); EST 18.7%

Cipla: Jefferies on Cipla Maintains Underperform with Target Price of ₹1,120 as it sees only ~12% upside even in a blue-sky scenario, remains bearish versus its bullish view on Mankind, and believes Cipla’s bull case relies on timely approval of two US drugs, which it considers unlikely.

 09 Jul 2026 08:58 AM

Cipla: Jefferies on Cipla Maintains Underperform with Target Price of ₹1,120 as it sees only ~12% upside even in a blue-sky scenario, remains bearish versus its bullish view on Mankind, and believes Cipla’s bull case relies on timely approval of two US drugs, which it considers unlikely.

Cipla: Co to Consider Q1 Results on July 23

 01 Jul 2026 02:16 PM

Cipla: Co to Consider Q1 Results on July 23

Cipla: Co. Grows Manufacturing for Respiratory and Specialty Products in India, China, and the U.S. - BS

 17 Jun 2026 09:03 AM

Cipla: Co. Grows Manufacturing for Respiratory and Specialty Products in India, China, and the U.S. - BS

Cipla Ltd: Appoints Mr. Shivam Puri As New CEO, Formerly At Hindustan Unilever, Jubilant Foodworks, And ITC.

 16 Jun 2026 01:11 PM

Cipla Ltd: Appoints Mr. Shivam Puri As New CEO, Formerly At Hindustan Unilever, Jubilant Foodworks, And ITC.

Cipla: USFDA Labels CIPLA's Goa Facility Inspection As Voluntary Action Indicated With Observations, No Immediate Action Required.

 11 Jun 2026 01:56 PM

Cipla: USFDA Labels CIPLA's Goa Facility Inspection As Voluntary Action Indicated With Observations, No Immediate Action Required.